Clinical comparison · Weight loss
Semaglutide vs 5-Amino-1MQ
Semaglutide is a GLP-1 injectable. 5-Amino-1MQ is an oral NNMT inhibitor that restores adipocyte NAD+ metabolism.
Attribute
Semaglutide
5-Amino-1MQ
Mechanism
GLP-1 receptor agonist. Delays gastric emptying, boosts satiety, augments insulin secretion.
Small-molecule NNMT inhibitor. Restores NAD+/SAM pool, increases adipocyte metabolic activity.
Standard dosing
0.25 mg weekly, titrated q4 weeks to a 1.7–2.4 mg maintenance dose.
50–150 mg orally daily.
Indications
- Medical weight loss
- Metabolic syndrome adjunct
- Type 2 diabetes (branded)
- Body composition
- Metabolic health
- Adjunct to GLP-1 or GH programs
Strengths
- Long clinical history
- Simpler side-effect profile at low doses
- Lower cost per week
- Oral dosing
- Non-hormonal metabolic lever
- Preserves lean mass
Cautions
- Slower weight-loss curve than tirzepatide
- GI side effects during titration
- MTC / MEN2 contraindication
- Emerging clinical evidence
- Not a standalone weight-loss agent
Choose 5-Amino-1MQ when
Patient wants an oral non-hormonal adjunct that preserves lean mass through the program.
Wholesale 5-Amino-1MQ →FAQs
- Can these be combined?
- Yes. 5-Amino-1MQ pairs well with GLP-1 titration for lean-mass preservation and metabolic support.
- Is 5-Amino-1MQ a peptide?
- No, it's a small-molecule NNMT inhibitor. It sits in peptide-adjacent metabolic protocols.